. 2022 Aug 10;5(8):e2225973. doi: 10.1001/jamanetworkopen.2022.25973

Table 3. Correlations Between Surrogate End Points and OS Among Cancer Indications Without Documented OS Benefit.

Correlation between surrogate end points and OS^a	Indication, No. (%)
Correlation between surrogate end points and OS^a	Without documented OS benefit (n = 73)	Documented lack of OS benefit (n = 34)	OS benefit unknown (n = 13)	OS benefit not evaluable (n = 26)
Published surrogate correlation studies^b	38 (52.1)	23 (67.6)	7 (53.8)	8 (30.8)
High (r≥0.85)	10 (26.3)	6 (26.1)	4 (57.1)	0
Medium (r = 0.7 to <0.85)	7 (18.4)	5 (21.7)	1 (14.3)	1 (12.5)
Low (r≤0.7)	21 (55.3)	12 (52.2)	2 (28.6)	7 (87.5)
No published surrogate correlation studies^b	35 (47.9)	11 (32.3)	6 (46.1)	18 (69.2)

Abbreviation: OS, overall survival.

^{^a}

Correlation information based on published literature (see eTable 11 in the Supplement for further detail).

^{^b}

For specific cancer type and line of therapy.